Healthcare: 45%
Research and Development: 30%
Agriculture and Food Industry: 25%

TOP 3 Markets:
USA: 40%
Europe: 35%
Asia-Pacific: 25%

Oxford Nanopore Technologies plc generates the majority of its revenues from the healthcare sector, followed by research and development, and the agriculture and food industry. This diversification enables the company to benefit from various growth opportunities in these sectors.

The USA is the largest market for the company, driven by strong demand for innovative sequencing technologies. Europe and the Asia-Pacific region closely follow, with both regions also making significant contributions to the company's total revenue.

Production Location: Oxford, United Kingdom

Oxford Nanopore Technologies plc mainly produces its products in Oxford, Great Britain. The company is known for its innovative DNA sequencing technology and has expanded its production capacities in the region to meet the increasing demand.

In addition, the company is investing in research and development to further optimize its production processes and develop new technologies. The strategic location in Oxford enables the company to benefit from proximity to academic institutions and a well-educated workforce pool.

Focus on Research and Development: Increase by 20% in Budget (2025)

Expansion of Product Range: Introduction of new sequencing technologies (2025)

International Expansion: Market entry into Asia and Latin America (2024-2025)

Oxford Nanopore Technologies plc pursues a growth strategy that heavily emphasizes innovation and technological advancement. The company has increased its budget for research and development by 20% to develop new sequencing technologies and enhance existing products.

Another focus is on expanding the product range. In 2025, the company plans to introduce new sequencing technologies that are intended to have a broader application in genomics and diagnostics.

Additionally, Oxford Nanopore aims for international expansion, particularly in high-growth markets such as Asia and Latin America. This geographical diversification is intended to unlock new revenue sources and strengthen the company's market presence.

Main raw materials: High-purity silicon wafers, biochemicals, electronic components
Countries of origin: USA, China, Germany

Oxford Nanopore Technologies plc specializes in the production of DNA sequencing technologies. For their products, they import high-purity silicon wafers, which are needed for the production of sensors, mainly from the USA and Germany. Biochemicals essential for the sequencing processes are sourced from various countries, with the USA and China being important suppliers. Electronic components used in the sequencing devices are also imported from China and other Asian countries.

These material imports are crucial for the production and further development of their innovative technologies. Oxford Nanopore pays attention to sourcing high-quality raw materials to ensure the efficiency and accuracy of their products.

Market share: Estimated 20% in the field of DNA sequencing (2026)
Research expenditure: £150 million (2025)
Patent portfolio: Over 500 patents (2026)

Oxford Nanopore Technologies plc has established itself as a significant player in the field of DNA sequencing. The company's competitive advantage lies primarily in its innovative technology, which enables real-time sequencing of DNA with portable devices. This provides flexibility and speed that many competitors do not achieve.

The company continuously invests in research and development, as highlighted by the high research expenditure of £150 million in 2025. These investments help to further improve the technology and explore new applications.

A strong patent portfolio with over 500 patents secures Oxford Nanopore a technological edge and protects its innovations from imitators. These strategic measures strengthen the market position and provide a significant competitive advantage over other companies in the industry.

Institutional Investor Share: 45% (estimated, 2026)

Insider Buys/Sells: No significant transactions reported (2026)

The institutional investor share in Oxford Nanopore Technologies plc is approximately 45%. This indicates a strong interest from institutional investors, reflecting confidence in the company's long-term growth prospects.

In 2026, no significant insider buys or sells were reported. This could suggest that the management and other insiders are satisfied with the current company strategy and valuation.

Market share of Oxford Nanopore Technologies: 12% (estimated for 2026)

Top competitors and their market shares:

1. Illumina, Inc.: 45%
2. Thermo Fisher Scientific Inc.: 20%
3. Pacific Biosciences of California, Inc.: 10%
4. BGI Group: 8%
5. Qiagen N.V.: 5%

Oxford Nanopore Technologies has established itself as a significant player in the field of DNA sequencing in recent years. The 12% market share indicates that the company has a solid position in the market, although it lags behind industry leaders Illumina and Thermo Fisher Scientific.

The moat of Oxford Nanopore lies in its unique nanopore-based sequencing technology, enabling real-time analysis and portable devices. This technology offers flexibility and mobility, providing an advantage in certain application areas.

Compared to competitors, Illumina has a stronger moat due to its established market presence, comprehensive product range, and strong customer loyalty. Thermo Fisher Scientific benefits from its broad diversification and extensive resources.

While Oxford Nanopore has a technological advantage in specific niches, competition remains intense, and larger companies have a significant advantage due to their economies of scale and established networks.

Revenue Growth: 18% (2025) Research and Development Expenses: 25% of Revenue (2025) Market Share in Genomic Sequencing: 12% (2025)

Oxford Nanopore Technologies plc recorded a revenue growth of 18% in 2025, driven by increasing demand for its innovative genomic sequencing technologies. The company is heavily investing in research and development, with 25% of revenue allocated to this area to secure its technological leadership and develop new products.

With a market share of 12% in the genomic sequencing sector, Oxford Nanopore demonstrates a significant position in a growing market segment. Continuous investments in research and development could enable the company to further expand its market position and benefit from future technological advancements.

Overall, the strong growth momentum and strategic focus on innovation suggest that Oxford Nanopore Technologies could be an attractive investment opportunity for investors interested in long-term growth.

Dividend payment: No dividend (as of 2026)

Oxford Nanopore Technologies plc has not paid any dividends so far. The company is strongly focused on growth and investments in research and development to further expand its market position in the field of DNA sequencing technology.

As Oxford Nanopore operates in an innovative and fast-paced technology sector, it is common for such companies to reinvest profits to maximize long-term growth opportunities. Therefore, it is unlikely that a dividend payment will be introduced in the near future as long as the company continues to pursue its growth strategy.